Information Provided By: 
Fly News Breaks for June 6, 2017
ALKS
Jun 6, 2017 | 08:49 EDT
The FDA's approval of a two-month dose duration option for Alkermes' Aristada adds to the long-acting injectable formulation of aripiprazole's advantages over Otsuka's Abilify Maintena, Leerink analyst Paul Matteis tells investors in a research note. The approval adds a "much-needed boost" to the franchise as the launch has been off to a "slow, below consensus start," the analyst writes. He remains optimistic that Aristada will capture market share and reiterates an Outperform rating on Alkermes.
News For ALKS From the Last 2 Days
